Cargando…
Comparison of Long-term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis
BACKGROUND/AIMS: The tumor necrosis factor-α inhibitors infliximab and adalimumab are standard treatments for moderate to severe ulcerative colitis (UC). However, there has been no head-to-head comparison of treatment efficacy and outcomes between the two agents. The aim of this study was to compare...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial Office of Gut and Liver
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960969/ https://www.ncbi.nlm.nih.gov/pubmed/32616683 http://dx.doi.org/10.5009/gnl19433 |